ArticleJournal of extracellular vesicles2026
Yersinia enterocolitica O:3 Outer Membrane Vesicles as a Platform for Complement Activation.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lipopolysaccharide (LPS) is the major component of the outer membrane vesicles (OMVs) of Gram-negative bacteria. We hypothesized that OMVs-induced complement activation contributes to the development of systemic inflammatory response syndrome (SIRS). Yersinia enterocolitica O:3 (YeO3) variants synthesizing LPS of various chemotypes (S, Ra, Rd1, Re) were used as model microorganisms. OMVs activated complement more potently than parental bacteria or homologous LPS, independently of chemotype. A high molecular weight polysaccharide fraction, distinct from LPS, was recognized by serum mannose-binding lectin (MBL). In vivo experiments demonstrated that complement depletion weakened the hallmarks of OMVs-induced SIRS in mice. LPS chemotype affected the biodistribution of OMVs and long O-specific polysaccharide protected them from clearance. Chemotype influenced OMVs secretion with their highest release by bacteria with LPS reduced to the inner core and lipid A (Rd1). The shift from environmental to host's temperature stimulated secretion of smaller OMVs, with less-toxic, tetra-acyl lipid A. Our data are consistent with a contribution of OMVs to Yersinia pathogenicity through complement activation. Their potency as complex virulence factor is influenced by size, length of oligo-/polysaccharide chain, and lipid A form. This study comprehensively characterizes OMV-complement interactions in YeO3, extending the knowledge of mechanisms previously established for other Gram-negative bacteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.